Oncogene-Mediated Alterations in Chromatin Conformation

Total Page:16

File Type:pdf, Size:1020Kb

Oncogene-Mediated Alterations in Chromatin Conformation Oncogene-mediated alterations in chromatin conformation David S. Rickmana,1, T. David Soongb,1, Benjamin Mossa, Juan Miguel Mosqueraa, Jan Dlabalb, Stéphane Terrya, Theresa Y. MacDonalda, Joseph Tripodic, Karen Buntingd, Vesna Najfeldc, Francesca Demichelisb,e, Ari M. Melnickd,f, Olivier Elementob,2, and Mark A. Rubina,f,2,3 Departments of aPathology and Laboratory Medicine and dMedicine, bDepartment of Physiology and Biophysics, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, and fWeill Cornell Cancer Center, Weill Cornell Medical College, New York, NY 10065; cTumor Cytogenetics Laboratory, Department of Pathology, Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY 10029; and eCentre for Integrative Biology, University of Trento, 38122 Trento, Italy Edited* by Eric S. Lander, The Broad Institute of MIT and Harvard, Cambridge, MA, and approved April 24, 2012 (received for review August 3, 2011) Emerging evidence suggests that chromatin adopts a nonrandom Results 3D topology and that the organization of genes into structural ERG Overexpression Is Associated with Chromatin Topology. To test hubs and domains affects their transcriptional status. How chroma- our hypothesis, we used stable isogenic, normal benign prostate tin conformation changes in diseases such as cancer is poorly un- epithelial cell lines (RWPE1) (21) that differ with respect to derstood. Moreover, how oncogenic transcription factors, which ERG overexpression (17) (Fig. S1A). To test whether ERG bind to thousands of sites across the genome, influence gene reg- overexpression is associated with global changes in chromatin ulation by globally altering the topology of chromatin requires structure, we performed unbiased chromatin interaction mapping further investigation. To address these questions, we performed using the Hi-C technique (22) from both RWPE1-ERG and unbiased high-resolution mapping of intra- and interchromosome RWPE1-GFP cells, with biological replicates (Fig. 1A and Fig. interactions upon overexpression of ERG, an oncogenic transcrip- S1A). Successful fill-in and ligation were determined as previously tion factor frequently overexpressed in prostate cancer as a result of reported (22) by testing for a known interaction between two a gene fusion. By integrating data from genome-wide chromosome distant genomic loci located on chromosome 6 (23) (Fig. S1B). conformation capture (Hi-C), ERG binding, and gene expression, we The Hi-C libraries were paired-end sequenced using an Illumina demonstrate that oncogenic transcription factor overexpression is GAIIx platform. Following alignment to the human genome associated with global, reproducible, and functionally coherent (hg18) and filtering to remove unligated and self-ligated DNA, changes in chromatin organization. The results presented here have we identified intrachromosomal (or cis-) and interchromosomal broader implications, as genomic alterations in other cancer types (or trans-) interactions in both RWPE1 cell lines. Correlation frequently give rise to aberrant transcription factor expression, e.g., α matrices obtained from independent biological replicates were EWS-FLI1, c-Myc, n-Myc, and PML-RAR . highly similar in both cell lines (Pearson’s correlation coefficient r = 0.99), indicating that the interaction patterns are highly re- ounting evidence suggests that many genes dynamically producible. Biological replicate interactions were therefore com- Mcolocalize to shared nuclear compartments that favor gene bined for further analyses. In total, we identified 18.4 million activation or silencing (1–3). As demonstrated by chromosome intrachromosomal (or cis-) and 18.3 million interchromosomal (or conformation capture (3C) (4), ligand-bound androgen recep- trans-) interactions in RWPE1-ERG cells (Dataset S1). We also tors (AR) and estrogen receptors mediate looped chromatin identified 16.9 million cis- and 18.6 million trans-interactions in structures resulting in coordinated transcription of target genes RWPE1-GFP cells. To visualize global patterns of cis-interactions, we binned the (5, 6). In embryonic carcinoma cells, the PolyComb complex – subunit EZH2 represses some of its target genes via the for- genome (chromosomes 1 22, X) into 1-Mb intervals and calcu- lated the ratio between observed and expected number of mation of similar looped chromatin structures (7). Trans-inter- interactions connecting each interval pair. We then generated actions that regulate gene expression have also been reported correlation heat maps depicting the extent to which pairs of – (8 10). These data suggest that oncogenic transcriptional regu- genomic intervals interact with the same intervals, on the basis of lators are capable of inducing changes in chromatin structures. the assumption that if two loci are close in nuclear space, their These studies have mainly focused on local chromatin structures, patterns of interaction with other loci should be highly corre- and it is still unclear whether more global changes occur in the lated. Confirming prior observations (22), the heat maps showed process of oncogene-mediated transformation. A broader im- plication of these observations is that global chromatin organi- zation changes could impact functional and phenotypic aspects Author contributions: D.S.R., T.D.S., O.E., and M.A.R. designed research; D.S.R., T.D.S., B.M., J.D., S.T., T.Y.M., J.T., V.N., and O.E. performed research; T.D.S., K.B., F.D., A.M.M., of cancer. and O.E. contributed new reagents/analytic tools; D.S.R., T.D.S., B.M., J.M.M., J.D., S.T., To globally investigate oncogene-mediated chromatin struc- J.T., V.N., O.E., and M.A.R. analyzed data; and D.S.R., T.D.S., J.D., S.T., O.E., and M.A.R. ture changes we focused on ERG, the ETS-family transcription wrote the paper. factor most frequently rearranged and overexpressed in prostate The authors declare no conflict of interest. cancer through the TMPRSS2-ERG and other gene fusions in- *This Direct Submission article had a prearranged editor. volving androgen-responsive promoters (11–13). ERG interacts Freely available online through the PNAS open access option. MEDICAL SCIENCES with several cofactors (14) and other transcription factors in- Data deposition: Hi-C and ChIPseq data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. cluding AR to regulate the expression of thousands of genes that GSE37752). favor dedifferentiation, cell invasion, and neoplastic transforma- 1D.S.R. and T.D.S. contributed equally to this work. – tion of prostate epithelium when overexpressed (15 20). We 2O.E. and M.A.R. contributed equally to this work. therefore hypothesized that changes in global gene expression 3To whom correspondence should be addressed. E-mail: [email protected]. induced by ERG overexpression could be associated with global This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. changes in the 3D structure of chromosomes. 1073/pnas.1112570109/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1112570109 PNAS | June 5, 2012 | vol. 109 | no. 23 | 9083–9088 Downloaded by guest on October 2, 2021 A + ERG abrogated in the presence of ERG (P = 0.01, Fisher’s exact test; Fig. S3D). To test this result, we performed targeted PCR from Remove x-link 3C libraries (3C-PCR) generated from asynchronous cells from Fill (biotin-dCTP) Shear/ Paired-end X-link Hind III Digested Chromatin Ligate Ligated DNA/ pull down Hi-C sequence Hi-C the two cell lines. Consistent with the Hi-C data, the interaction chromatin prep protein library Dataset prep between the promoters of TMPRSS2 and TFF3 was enriched in - ERG control cells (RWPE1-GFP) and depleted in the ERG over- expressing cells (Fig. S3D). One of the most statistically significant cis-interaction changes involved two distant regions on chromosome 6 (regions between B p22.3–12.3 and q22.31–25.32); these regions interact significantly more in cells overexpressing ERG compared with control cells (Fig. 2A and Fig. S3A). We also observed loss of interactions in RWPE1-ERG cells [e.g., chromosome 10 (regions between p15.3– p13 and q21.3–25.1, Fig. S3B) and chromosome 13 (regions be- tween q12.11–13.1 and q13.1–21.1, Fig. S3C)]. Consistent with previous findings (22), we detected more trans-interactions be- tween small, gene-rich chromosomes (e.g., chromosomes 16–22) than between larger chromosomes in both RWPE1-ERG and − − RWPE1-GFP cells (P =1.4× 10 9 and P =4.1× 10 6,re- spectively, Mann–Whitney tests; Fig. S4A). Moreover, specific regions of chromosomes tended to interact preferentially on the basis of high-resolution heat maps of normalized interactions be- tween all cytogenetic bands (Fig. S4B). RWPE-1 cells have been reported to be primarily diploid and to harbor specific trans- locations involving chromosomes 9, 12, 18, and 21 in at least 90% of the cells (21). To determine whether additional, unreported translocations accounted for the enriched Hi-C interactions, we performed spectral karyotyping of both cell lines (24). The kar- yotypes observed in the two cell lines were identical, barring a der (13)t(13;15)(q12;q12) unique to ERG overexpressing cells (Fig. S5A), and also detectable using chromosome painting (Fig. S5B). Accordingly, our Hi-C data show a specific increase in interaction between chromosome 13 and chromosome 15 in RWPE1-ERG Fig. 1. Specific cis-interactions that depend on ERG expression. (A) Sche- cells (Figs. S4B and S5C). The spectral karyotyping results thus matic representation of the experimental flow of the Hi-C experiments. Red indicate that changes in interchromosomal interactions detected symbols refer to ERG protein and white symbols refer to other DNA-inter- by Hi-C sometimes represent translocations. However, further acting proteins. (B) Circos plot depicting chromosomes 1–22 and X anno- inspection of the Hi-C and spectral karyotype data shows that tated for ERG binding on the basis of ChIP-seq data (normalized reads shown several ERG- or GFP-specific trans-interactions revealed by Hi-C in orange) and 1,266 differentially expressed genes annotated on the basis are unlikely to be translocations.
Recommended publications
  • A Novel Ve-Zinc Nger-Related-Gene Signature Related to Tumor Immune
    A novel ve-zinc nger-related-gene signature related to tumor immune microenvironment allows for treatment stratication and predicts prognosis in clear cell renal cell carcinoma patients Feilong Zhang Beijing Chaoyang Hospital Jiyue Wu Beijing Chaoyang Hospital Jiandong Zhang Beijing Chaoyang Hospital Peng Cao Beijing Chaoyang Hospital Zejia Sun Beijing Chaoyang Hospital Wei Wang ( [email protected] ) Beijing Chaoyang Hospital https://orcid.org/0000-0003-2642-3338 Research Keywords: Posted Date: February 23rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-207677/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/25 Abstract Background Clear cell renal cell carcinoma (ccRCC) is one of the most prevalent renal malignant tumors, which survival rate and quality of life of ccRCC patients are not satisfactory. Therefore, identication of prognostic biomarkers of ccRCC patients will contribute to early and accurate clinical intervention and treatment, and then improve their prognosis. Methods We downloaded the original expression data of mRNAs from The Cancer Genome Atlas database and the zinc nger(ZNF)-related genes (ZRGs) from UniProt online database. Differentially expressed ZRGs (DE- ZRGs) was screened from tumor and adjacent nontumor tissues and functional enrichment analysis was conducted out. A ve-ZRG signature were constructed by univariate Cox regression, least absolute shrinkage and selection operator and multivariate Cox regression. Furthermore, we screened out independent prognosis-related factors to build a nomogram by univariate and multivariate Cox regression. Potential biological pathways of ve ZRGs were analyzed by Gene Set Enrichment Analysis (GSEA). Then, we further quantitatively analyze immune inltration and evaluate tumor microenvironment by single sample GSEA.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Downloaded in Aug 2019
    ARTICLE https://doi.org/10.1038/s41467-021-24473-2 OPEN IL-15 and PIM kinases direct the metabolic programming of intestinal intraepithelial lymphocytes Olivia J. James1, Maud Vandereyken1, Julia M. Marchingo 2, Francois Singh1, Susan E. Bray3, Jamie Wilson4, ✉ Andrew G. Love1 & Mahima Swamy 1 1234567890():,; Intestinal intraepithelial lymphocytes (IEL) are an abundant population of tissue-resident T cells that protect and maintain the intestinal barrier. IEL respond to epithelial cell-derived IL-15, which is complexed to the IL-15 receptor α chain (IL-15/Rα). IL-15 is essential both for maintaining IEL homeostasis and inducing IEL responses to epithelial stress, which has been associated with Coeliac disease. Here, we apply quantitative mass spectrometry to IL-15/Rα- stimulated IEL to investigate how IL-15 directly regulates inflammatory functions of IEL. IL-15/ Rα drives IEL activation through cell cycle regulation, upregulation of metabolic machinery and expression of a select repertoire of cell surface receptors. IL-15/Rα selectively upregu- lates the Ser/Thr kinases PIM1 and PIM2, which are essential for IEL to proliferate, grow and upregulate granzyme B in response to inflammatory IL-15. Notably, IEL from patients with Coeliac disease have high PIM expression. Together, these data indicate PIM kinases as important effectors of IEL responses to inflammatory IL-15. 1 MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK. 2 Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK. 3 NHS Research Scotland, Tayside Tissue Biorepository, University of Dundee, Dundee, UK. 4 Department of ✉ Pathology, NHS Tayside, Ninewells Hospital, Dundee, UK.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Anti-CD18 / LFA1 Beta Antibody (ARG41484)
    Product datasheet [email protected] ARG41484 Package: 100 μl anti-CD18 / LFA1 beta antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CD18 / LFA1 beta Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CD18 / LFA1 beta Antigen Species Human Immunogen Recombinant protein of Human CD18 / LFA1 beta. Conjugation Un-conjugated Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse thymus Calculated Mw 85 kDa Observed Size ~ 98 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw www.arigobio.com 1/3 cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGB2 Gene Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Background This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers.
    [Show full text]
  • Rabbit Anti-Phospho-CD18-SL10462R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-Phospho-CD18 SL10462R-FITC Product Name: Anti-Phospho-CD18 (Thr758)/FITC Chinese Name: FITC标记的磷酸化整合素β2/Integrin β2抗体 CD18 (Phospho Thr758); CD18 (Phospho-Thr758); CD18 (Phospho T758); p-CD18 (T758); p-CD18 (Thr758); Integrin beta 2; 95 subunit beta; CD 18; CD18; Cell surface adhesion glycoprotein LFA 1/CR3/P150,959 beta subunit precursor); Cell surface adhesion glycoproteins LFA 1/CR3/p150,95 subunit beta; Cell surface adhesion glycoproteins LFA-1/CR3/p150; Complement receptor C3 beta subunit; Complement Alias: receptor C3 subunit beta; Integrin beta chain beta 2; Integrin beta-2; Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); ITB2_HUMAN; ITGB2; LAD; LCAMB; Leukocyte associated antigens CD18/11A, CD18/11B, CD18/11C; Leukocyte cell adhesion molecule CD18; LFA 1; LFA1; Lymphocyte function associated antigen 1; MAC 1; MAC1; MF17; MFI7; OTTHUMP00000115278; OTTHUMP00000115279; OTTHUMP00000115280; OTTHUMP00000115281; OTTHUMP00000115282. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Horse,Rabbit,Sheep,Guinea Pig, Flow-Cyt=1:50-200ICC=1:50-200IF=1:50-200www.sunlongbiotech.com Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 82kDa Form: Lyophilized or Liquid Concentration: 1mg/ml KLH conjugated synthesised phosphopeptide derived from human CD18 around the immunogen: phosphorylation site of Thr758 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Molecular Programming of Tumor-Infiltrating CD8 T Cells and IL15 Resistance
    Published OnlineFirst August 2, 2016; DOI: 10.1158/2326-6066.CIR-15-0178 Research Article Cancer Immunology Research Molecular Programming of Tumor-Infiltrating CD8þ T Cells and IL15 Resistance Andrew L. Doedens1, Mark P. Rubinstein1,2, Emilie T. Gross3, J. Adam Best1, David H. Craig2, Megan K. Baker2, David J. Cole2, Jack D. Bui3, and Ananda W. Goldrath1 Abstract Despite clinical potential and recent advances, durable immu- in the lung and spleen were activated and dramatically expanded. þ notherapeutic ablation of solid tumors is not routinely achieved. Tumor-infiltrating CD8 T cells exhibited cell-extrinsic and cell- IL15expandsnaturalkillercell(NK),naturalkillerTcell(NKT)and intrinsic resistance to IL15. Our data showed that in the case of þ CD8 T-cell numbers and engages the cytotoxic program, and thus persistent viral or tumor antigen, single-agent systemic IL15cx is under evaluation for potentiation of cancer immunotherapy. We treatment primarily expanded antigen-irrelevant or extratumoral þ found that short-term therapy with IL15 bound to soluble IL15 CD8 Tcells.Weidentified exhaustion, tissue-resident memory, þ receptor a–Fc (IL15cx; a form of IL15 with increased half-life and and tumor-specific molecules expressed in tumor-infiltrating CD8 activity) was ineffective in the treatment of autochthonous PyMT T cells, which may allow therapeutic targeting or programming þ murine mammary tumors, despite abundant CD8 T-cell infiltra- of specific subsets to evade loss of function and cytokine resist- tion. Probing of this poor responsiveness revealed that IL15cx ance, and, in turn, increase the efficacy of IL2/15 adjuvant cytokine þ only weakly activated intratumoral CD8 T cells, even though cells therapy.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Supplemental Figure S1. Distinct difference in expression of 576 sensome genes comparing cortex versus microglia. (A) This heatmap shows all 576 sensome candidate genes ordered by DE and with the left column shows if the gene is present in the “Hickman et al. sensome” Supplemental Figure S2. Mouse sensome and human sensome genes categorized by group. (A) Bar graph showing the number of mouse and human sensome genes per group (Cell-Cell Interactions, Chemokine and related receptors, Cytokine receptors, ECM receptors, Endogenous ligands receptors, sensors and transporters, Fc receptors, Pattern recognition and related receptors, Potential sensors but no known ligands and Purinergic and related receptors). Supplementary Figure S3. Overlap of ligands recognized by microglia sensome (A) Overlap between the ligands of the receptors from respectively human and mouse core sensome was shown using Venn Diagrams. (B) Ligands of human and mouse receptors categorized in groups (Glycoproteins, Cytokines, Immunoglobulin, Amino acids, Carbohydrates, Electrolytes, Lipopeptides, Chemokines, Neuraminic acids, Nucleic acids, Receptors, Lipids, Fatty acids, Leukotrienes, Hormones, Steroids and Phospholipids) and spread of different groups shown as parts of whole again highlighting that the distribution of ligands what the human and mouse sensome genes can sense (Categorization of ligands in Supplementary Table S1). Supplementary Figure S4. Microglia core sensome expression during aging. (A) Two-log fold change of microglia core sensome genes in aging mice derived from Holtman et al. [12]. (B) Accelerated aging model (ERCC1), with impaired DNA repair mechanism, shows changes of microglia core sensome expression [12]. (C) Microglia core sensome expression during aging in human derived from Olah et al.
    [Show full text]
  • Whole-Exome Sequencing Identifies Causative Mutations in Families
    BASIC RESEARCH www.jasn.org Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract Amelie T. van der Ven,1 Dervla M. Connaughton,1 Hadas Ityel,1 Nina Mann,1 Makiko Nakayama,1 Jing Chen,1 Asaf Vivante,1 Daw-yang Hwang,1 Julian Schulz,1 Daniela A. Braun,1 Johanna Magdalena Schmidt,1 David Schapiro,1 Ronen Schneider,1 Jillian K. Warejko,1 Ankana Daga,1 Amar J. Majmundar,1 Weizhen Tan,1 Tilman Jobst-Schwan,1 Tobias Hermle,1 Eugen Widmeier,1 Shazia Ashraf,1 Ali Amar,1 Charlotte A. Hoogstraaten,1 Hannah Hugo,1 Thomas M. Kitzler,1 Franziska Kause,1 Caroline M. Kolvenbach,1 Rufeng Dai,1 Leslie Spaneas,1 Kassaundra Amann,1 Deborah R. Stein,1 Michelle A. Baum,1 Michael J.G. Somers,1 Nancy M. Rodig,1 Michael A. Ferguson,1 Avram Z. Traum,1 Ghaleb H. Daouk,1 Radovan Bogdanovic,2 Natasa Stajic,2 Neveen A. Soliman,3,4 Jameela A. Kari,5,6 Sherif El Desoky,5,6 Hanan M. Fathy,7 Danko Milosevic,8 Muna Al-Saffar,1,9 Hazem S. Awad,10 Loai A. Eid,10 Aravind Selvin,11 Prabha Senguttuvan,12 Simone Sanna-Cherchi,13 Heidi L. Rehm,14 Daniel G. MacArthur,14,15 Monkol Lek,14,15 Kristen M. Laricchia,15 Michael W. Wilson,15 Shrikant M. Mane,16 Richard P. Lifton,16,17 Richard S. Lee,18 Stuart B. Bauer,18 Weining Lu,19 Heiko M. Reutter ,20,21 Velibor Tasic,22 Shirlee Shril,1 and Friedhelm Hildebrandt1 Due to the number of contributing authors, the affiliations are listed at the end of this article.
    [Show full text]